HROW

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

Dollar change +0.09
Percentage change 0.24	%

Peers: OCUL EYPT PRPH AKTX ALDX EDIT QURE TTOO CRSP BNGO

| Held by: VTI IWM VXF IWO VTWO SCHA VHT DWAS IWC PTH

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.94	Insider Own	13.82%	Shs Outstand	35.61M	Perf Week	-0.58%
Market Cap	1.35B	Forward P/E	67.01	EPS next Y	0.56	Insider Trans	0.00%	Shs Float	30.69M	Perf Month	-27.22%
Income	-33.41M	PEG	-	EPS next Q	0.02	Inst Own	58.91%	Short Float	9.35%	Perf Quarter	-10.01%
Sales	169.14M	P/S	7.97	EPS this Y	12.33%	Inst Trans	11.58%	Short Ratio	5.45	Perf Half Y	107.45%
Book/sh	1.62	P/B	23.41	EPS next Y	185.93%	ROA	-10.48%	Short Interest	2.87M	Perf Year	287.12%
Cash/sh	2.04	P/C	18.57	EPS next 5Y	15.00%	ROE	-50.10%	52W Range	9.13 - 59.23	Perf YTD	238.04%
Dividend Est.	-	P/FCF	443.54	EPS past 5Y	-	ROI	-13.20%	52W High	-36.08%	Beta	0.68
Dividend TTM	-	Quick Ratio	1.44	Sales past 5Y	27.34%	Gross Margin	72.56%	52W Low	314.68%	ATR (14)	2.55
Dividend Ex-Date	-	Current Ratio	1.54	EPS Y/Y TTM	-109.79%	Oper. Margin	-5.07%	RSI (14)	37.50	Volatility	5.36% 6.95%
Employees	315	Debt/Eq	3.40	Sales Y/Y TTM	48.15%	Profit Margin	-19.75%	Recom	1.00	Target Price	59.85
Option/Short	Yes / Yes	LT Debt/Eq	3.40	EPS Q/Q	7.80%	Payout	-	Rel Volume	0.20	Prev Close	37.77
Sales Surprise	-6.71%	EPS Surprise	-128.57%	Sales Q/Q	43.75%	Earnings	Nov 13 AMC	Avg Volume	526.33K	Price	37.86
SMA20	-7.83%	SMA50	-19.03%	SMA200	32.07%	Trades		Volume	96,168	Change	0.24%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-04-24	Reiterated	B. Riley Securities	Buy	$73 → $69
Apr-11-24	Initiated	Craig Hallum	Buy	$24
Sep-08-22	Resumed	B. Riley Securities	Buy	$17
Oct-14-21	Resumed	B. Riley Securities	Buy	$16
Sep-24-21	Initiated	Aegis Capital	Buy	$15
Jul-02-21	Initiated	Ladenburg Thalmann	Buy	$14.25

Nov-21-24 07:00AM	Harrows ImprimisRx Subsidiary Receives $34.9 Million Unanimous Jury Verdict Award in ImprimisRx, LLC v. OSRX, Inc. (Business Wire)
Nov-20-24 07:00AM	Melt Pharmaceuticals Reports Positive Phase 3 Topline Efficacy Results for MELT-300, Its Lead Product Candidate for Opioid-Free, Sublingual Procedural Sedation in Patients Undergoing Cataract Surgery (Business Wire) +6.90%
Nov-15-24 07:00AM	Harrow Announces Participation in Upcoming Investor Conferences (Business Wire) -8.98%
02:06AM	Harrow Inc (HROW) Q3 2024 Earnings Call Highlights: Record Revenue and Strategic Growth Amid ... (GuruFocus.com)
Nov-13-24 04:34PM	Harrow Announces Third Quarter 2024 Financial Results (Business Wire) -17.26%
07:16AM	Loading…
07:16AM	Harrow Inc (HROW) Q3 2024 Earnings Report Preview: What To Look For (GuruFocus.com)
07:00AM	Harrow Launches Access and Affordability Program with Price Reductions for Branded Products (Business Wire)
Nov-12-24 07:00AM	Harrow Announces Market Access Wins for VEVYE (Business Wire)
Nov-07-24 07:00AM	Harrow Partners with Asembia to Enhance Provider and Patient Experience Through Nationwide Digital Services and Hub Support for Harrows Branded Eyecare Products (Business Wire)
Oct-31-24 07:00AM	Harrow To Report Third Quarter 2024 Financial Results After Market Close on November 13, 2024 (Business Wire)
Oct-10-24 07:00AM	Melt Pharmaceuticals Announces Dosing of Last Patient in Pivotal Phase 3 Study of Its Lead Product Candidate, MELT-300, for Needle- and Opioid-Free Sedation in Patients Undergoing Cataract Surgery (Business Wire)
Oct-03-24 07:00AM	Harrow Relaunches TRIESENCE (Business Wire) +8.44%
Oct-02-24 11:10AM	Harrow, Inc. (HROW): A Bull Case Theory (Insider Monkey)
Sep-25-24 12:02PM	Harrow Announces Nashville Expansion (Business Wire)
Sep-03-24 07:00AM	Harrow to Present at Three Investor Conferences in September in New York (Business Wire)
04:01PM	Loading…
Aug-07-24 04:01PM	Harrow Announces Second Quarter 2024 Financial Results (Business Wire) +54.32%
Jul-25-24 07:00AM	Harrow To Report Second Quarter 2024 Financial Results After Market Close on August 7, 2024 (Business Wire)
Jul-12-24 07:00AM	Harrow to Attend 2024 ASRS Annual Meeting (Business Wire)
Jul-09-24 07:00AM	Harrow Enters into 340B Prime Vendor Program Contract with Apexus for IHEEZO and Other Key Harrow Products (Business Wire)
Jul-02-24 11:52AM	HROW Stock Earnings: Harrow Beats EPS, Beats Revenue for Q2 2023 (InvestorPlace)
Jun-20-24 07:00AM	Harrow Provides TRIESENCE Relaunch Update (Business Wire) +12.92%
Jun-07-24 06:30AM	The Top 7 Growth Stocks to Buy and Hold Until 2030 (InvestorPlace)
Jun-06-24 08:00AM	Melt Pharmaceuticals Announces First Patient Dosed in Pivotal Phase 3 Program of Its Lead Product Candidate, MELT-300, for Needle- and Opioid-Free Sedation in Patients Undergoing Cataract Surgery (Business Wire)
Jun-05-24 07:00AM	Harrow Announces 52-Week Data from VEVYE ESSENCE-2 Open-Label Extension Study (Business Wire)
May-15-24 07:00AM	Harrow to Present at Two Investor Conferences in May (Business Wire)
May-13-24 08:55PM	HROW Stock Earnings: Harrow Health Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace) +34.55%
04:25PM	Harrow Health Q1 Core Net Loss Widens, Revenue Increases -- Shares Rise After-Hours (MT Newswires)
04:01PM	Harrow Announces First Quarter 2024 Financial Results (Business Wire)
07:00AM	Harrow Names Greg DiPasquale as Senior Vice President, Head of Commercial (Business Wire)
Apr-25-24 07:00AM	Harrow Will Release First Quarter 2024 Financial Results After Market Close on May 13, 2024 (Business Wire)
08:16AM	Loading…
Apr-02-24 08:16AM	Melt Pharmaceuticals Closes $24 Million Series B Preferred Stock Financing (Business Wire)
Mar-21-24 09:55AM	Harrow Health, Inc. (NASDAQ:HROW) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-19-24 09:52PM	HROW Stock Earnings: Harrow Health Misses EPS, Misses Revenue for Q4 2023 (InvestorPlace)
06:51PM	Harrow Inc (HROW) Reports Substantial Revenue Growth Amidst Net Loss Expansion in 2023 (GuruFocus.com)
05:45PM	Harrow Announces Fourth Quarter and Year-End 2023 Financial Results (Business Wire)
Mar-13-24 06:35AM	Harrow (HROW) Fell on Lowering the Guidance (Insider Monkey)
Mar-05-24 07:00AM	Harrow Will Release Fourth Quarter and Year-End 2023 Financial Results After Market Close on March 19, 2024 (Business Wire)
Mar-04-24 08:28PM	11 Best Small Cap Pharma Stocks to Invest In (Insider Monkey)
Feb-21-24 06:47AM	Heres How Harrow (HROW) Weighed on SRK Capitals Performance (Insider Monkey)
Feb-15-24 04:01PM	Harrow Licenses Canadian Rights to Apotex for Five Branded Ophthalmic Pharmaceutical Products (Business Wire)
Jan-29-24 07:00AM	Harrow Announces New Appointments to its Board of Directors (Business Wire)
Jan-11-24 07:00AM	Harrow Announces Availability of VEVYE (Cyclosporine Ophthalmic Solution) 0.1%, the First and Only Cyclosporine-Based Product Indicated for Treating Both Signs and Symptoms of Dry Eye Disease (Business Wire)
Jan-03-24 07:15AM	Melt Pharmaceuticals Provides Corporate Update (Business Wire)
07:00AM	Harrow Partners with Leading Healthcare Market Access Technology Platforms (Business Wire)
Dec-24-23 01:08PM	7 Short-Squeeze Stocks That Are Screaming for Speculation (InvestorPlace)
Nov-29-23 07:00AM	Harrow Completes Transfer of the TRIESENCE New Drug Application (Business Wire)
Nov-20-23 07:00AM	Harrow to Present at Two Investor Conferences in November (Business Wire) +5.58%
Nov-14-23 12:56PM	Harrow Health, Inc. (NASDAQ:HROW) Q3 2023 Earnings Call Transcript (Insider Monkey) -36.01%
Nov-13-23 05:07PM	Harrow Inc (HROW) Reports 50% Revenue Growth in Q3 2023 (GuruFocus.com)
04:01PM	Harrow Announces Third Quarter 2023 Financial Results (Business Wire)
Oct-30-23 08:00AM	Harrow Will Release Third Quarter 2023 Financial Results on November 13, 2023 (Business Wire)
Oct-24-23 07:00AM	Harrow Completes Transfer of NDAs and Launches FLAREX, NATACYN, TOBRADEX ST, VERKAZIA, and ZERVIATE in the U.S. (Business Wire)
Sep-29-23 08:00AM	Harrow Health, Inc. Changes Corporate Name to Harrow, Inc. (Business Wire)
Sep-26-23 08:00AM	Melt Pharmaceuticals Announces Exclusive Development and License Agreement with Catalent for Its Zydis® Fast-Dissolve Technology for Use in MELT-300 for Needle- and Opioid-Free Procedural Sedation (Business Wire) -5.20%
Sep-21-23 01:03PM	Opaleye Management Inc. Reduces Stake in Harrow Health Inc. (GuruFocus.com)
Aug-11-23 01:05PM	Harrow Health, Inc. (NASDAQ:HROW) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-10-23 09:54AM	Q2 2023 Harrow Health Inc Earnings Call (Thomson Reuters StreetEvents) -15.45%
Aug-09-23 04:14PM	Harrow: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Harrow Announces Second Quarter 2023 Financial Results (Business Wire)
Jul-31-23 07:00AM	Harrow Launches VIGAMOX® in the U.S. (Business Wire)
Jul-28-23 02:56PM	10 Best Small Cap Pharma Stocks to Buy (Insider Monkey)
Jul-26-23 03:42PM	Harrow Health inks deals for the rights to eight medications (American City Business Journals)
09:00AM	Harrow to Announce Second Quarter 2023 Financial Results on August 9, 2023 (Business Wire)
Jul-20-23 10:29AM	Strength Seen in Harrow (HROW): Can Its 17.8% Jump Turn into More Strength? (Zacks)
Jul-19-23 12:17PM	Why Shares of Harrow Health Are Jumping Wednesday (Motley Fool) +17.84%
07:00AM	Harrow Prices $60 Million Public Offering of Common Stock (Business Wire)
Jul-18-23 05:00PM	Harrow Acquires Santens Branded Ophthalmic Portfolio (Business Wire)
04:05PM	Harrow Provides Select Preliminary Second Quarter 2023 Financial Guidance (Business Wire)
04:04PM	Harrow Announces Proposed Public Offering of Common Stock (Business Wire)
04:01PM	Harrow Acquires U.S. and Canadian Commercial Rights to VEVYE® (Cyclosporine Ophthalmic Solution) 0.1% from Novaliq (Business Wire)
Jul-05-23 06:15PM	Harrow Health (HROW) Gains As Market Dips: What You Should Know (Zacks)
Jun-29-23 06:15PM	Harrow Health (HROW) Outpaces Stock Market Gains: What You Should Know (Zacks) +6.31%
Jun-23-23 06:15PM	Harrow Health (HROW) Flat As Market Sinks: What You Should Know (Zacks)
Jun-16-23 06:00PM	Harrow Health (HROW) Dips More Than Broader Markets: What You Should Know (Zacks)
May-17-23 08:00AM	Harrow to Participate in B. Riley Securities 23rd Annual Institutional Investor Conference on May 24, 2023 (Business Wire)
May-16-23 11:57AM	Harrow Health, Inc. (NASDAQ:HROW) Q1 2023 Earnings Call Transcript (Insider Monkey)
May-15-23 11:21AM	Analysts Initiate Coverage: 5 Stocks for Higher Returns (Zacks) -5.22%
May-12-23 01:48PM	Why Shares of Harrow Health Are Slumping Friday (Motley Fool) -18.58%
06:26AM	Q1 2023 Harrow Health Inc Earnings Call (Thomson Reuters StreetEvents)
May-11-23 05:15PM	Harrow Health (HROW) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:29PM	Harrow: Q1 Earnings Snapshot (AP Finance)
04:01PM	Harrow Announces First Quarter 2023 Financial Results (Business Wire)
May-08-23 12:07PM	Harrow Health (HROW) to Report Q1 Earnings: What's in the Offing? (Zacks)
May-04-23 08:00AM	Harrow to Launch FDA-Approved IHEEZO at the 2023 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting (Business Wire)
04:59AM	Zacks.com featured highlights Arcellx, Harrow Health, PROG, Chipotle Mexican Grill and Meta (Zacks)
May-03-23 06:44AM	5 Stocks With Recent Price Strength That Still Have Upside (Zacks)
May-02-23 04:42PM	Use New Analyst Coverage to Find Great Momentum Stocks to Buy in May (Zacks)
09:40AM	Is HCA Healthcare (HCA) Outperforming Other Medical Stocks This Year? (Zacks)
07:00AM	Harrow Launches ILEVRO®, NEVANAC®, and MAXIDEX® in the U.S. (Business Wire)
May-01-23 08:50AM	Here's Why Momentum in Harrow (HROW) Should Keep going (Zacks)
Apr-28-23 06:00PM	Harrow Health (HROW) Stock Sinks As Market Gains: What You Should Know (Zacks)
05:00AM	Zacks.com featured highlights Harrow Health and Disc Medicine Opco (Zacks)
Apr-27-23 08:05AM	2 Stocks in Focus as Analysts Initiate Coverage (Zacks)
08:00AM	Harrow to Announce First Quarter 2023 Financial Results on May 11, 2023 (Business Wire)
Apr-24-23 08:43AM	Harrow Health and CDW have been highlighted as Zacks Bull and Bear of the Day (Zacks)
07:09AM	Bull Of The Day: Harrow Health (HROW) (Zacks)
Apr-20-23 08:31AM	5 Small Hidden Gems to Pick From a Rangebound Wall Street (Zacks)
Apr-19-23 06:15PM	Harrow Health (HROW) Dips More Than Broader Markets: What You Should Know (Zacks)
08:31AM	Zacks.com featured highlights include Riley Exploration Permian, Harrow Health, Crawford, Tecnoglass and Lantheus Holdings (Zacks)
Apr-18-23 06:24AM	5 Stocks With Recent Price Strength to Maximize Your Gains (Zacks)

Harrow, Inc. engages in the development, production, and sale of innovative medications. It operates through the following segments: Pharmaceutical Compounding and Pharmaceutical Drug Development. The Pharmaceutical Compounding segment focuses on the operations of the ImprimisRx business. The company was founded by Mark L. Baum and Robert J. Kammer in January 2006 and is headquartered in Nashville, TN.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
SAHAREK JOHN P.	CEO of ImprimisRx	Sep 11 '24	Option Exercise	7.37	90,000	663,300	344,803	Sep 13 05:26 PM
Opaleye Management Inc.	10% Owner	Apr 25 '24	Buy	9.97	20,000	199,400	3,815,000	Apr 25 05:19 PM
Opaleye Management Inc.	10% Owner	Apr 23 '24	Buy	10.29	11,715	120,547	3,786,715	Apr 24 04:40 PM
Opaleye Management Inc.	10% Owner	Apr 24 '24	Buy	10.15	8,285	84,093	3,795,000	Apr 24 04:40 PM
Opaleye Management Inc.	10% Owner	Apr 19 '24	Buy	10.56	29,400	310,390	3,775,000	Apr 19 06:24 PM
Opaleye Management Inc.	10% Owner	Mar 28 '24	Buy	12.82	50,000	641,000	3,745,600	Mar 28 06:07 PM
BAUM MARK L	CHIEF EXECUTIVE OFFICER	Mar 22 '24	Buy	11.59	9,000	104,310	2,137,525	Mar 25 07:00 AM
Opaleye Management Inc.	10% Owner	Mar 20 '24	Buy	9.65	50,600	488,290	3,695,600	Mar 22 11:52 AM
SAHAREK JOHN P.	CEO of ImprimisRx	Mar 01 '24	Option Exercise	8.75	5,000	43,750	254,803	Mar 06 06:06 AM
SAHAREK JOHN P.	CEO of ImprimisRx	Feb 20 '24	Option Exercise	10.67	30,000	320,100	262,419	Feb 21 07:30 PM
BOLL ANDREW R.	CHIEF FINANCIAL OFFICER	Feb 20 '24	Option Exercise	10.67	45,000	480,150	586,569	Feb 21 07:29 PM
BAUM MARK L	CHIEF EXECUTIVE OFFICER	Feb 20 '24	Option Exercise	10.67	150,000	1,600,500	2,188,361	Feb 21 07:29 PM
BAUM MARK L	CHIEF EXECUTIVE OFFICER	Feb 07 '24	Option Exercise	7.71	15,400	118,734	2,038,361	Feb 08 07:30 AM
BOLL ANDREW R.	CHIEF FINANCIAL OFFICER	Feb 07 '24	Option Exercise	7.71	7,400	57,054	541,569	Feb 08 07:30 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Harrow Inc

Upgrade your FINVIZ experience